Hong Jun Hee, Nindra Udit, Nguyen Rebecca, Gassner Paul, Balakrishnar Bavanthi, Rutland Tristan
Department of Medical Oncology, Liverpool Hospital, Sydney, NSW, Australia.
Department of Urology, Liverpool Hospital, Sydney, NSW, Australia.
Case Rep Oncol. 2022 Nov 16;15(3):1055-1062. doi: 10.1159/000525842. eCollection 2022 Sep-Dec.
Prostate adenocarcinoma with testicular metastasis is rare, present in up to 4% of autopsy diagnoses, and presents symptomatically in less than 0.5% of cases. We report an unusual case of a 55-year-old male who developed a symptomatic testicular metastasis from primary prostate cancer 4 years after initial diagnosis of metastatic castrate-sensitive prostate cancer with nodal and bone-only involvement. The patient had orchidectomy, histologically confirming the metastasis and revealing sparing of the spermatic cord. Prior treatment for his metastatic castrate-sensitive prostate cancer had included androgen deprivation therapy and upfront docetaxel chemotherapy. He had received palliative radiotherapy for symptomatic bone metastasis and managed on enzalutamide for castrate-resistant disease for the preceding 22 months with ongoing PSA response at the time of diagnosis of new testicular metastasis, with a further significant PSA response following his "testicular metastasectomy." At the time of diagnosis of testicular metastasis, he did not have any evidence of other visceral metastases, and his metastatic disease otherwise remained radiologically stable. We describe his disease course, treatment and outline the rare nature of his case of testicular metastasis from prostate cancer.
前列腺腺癌伴睾丸转移较为罕见,在尸检诊断中占比高达4%,而出现症状的病例不到0.5%。我们报告一例罕见病例,一名55岁男性在最初诊断为仅伴有淋巴结和骨转移的转移性去势敏感性前列腺癌4年后,出现了原发性前列腺癌的有症状睾丸转移。患者接受了睾丸切除术,组织学检查证实了转移,并显示精索未受侵犯。他之前针对转移性去势敏感性前列腺癌的治疗包括雄激素剥夺疗法和一线多西他赛化疗。他曾因有症状的骨转移接受姑息性放疗,并在之前的22个月里接受恩杂鲁胺治疗去势抵抗性疾病,在诊断出新的睾丸转移时PSA持续有反应,“睾丸转移瘤切除术”后PSA进一步显著下降。在诊断出睾丸转移时,他没有任何其他内脏转移的证据,其转移性疾病在放射学上保持稳定。我们描述了他的病程、治疗情况,并概述了他这种前列腺癌睾丸转移病例的罕见性。